Clinical trials
Non-Hodgkin Lymphoma clinical trials
Below are recruiting non-hodgkin lymphoma clinical trials, each written for real people, not researchers. We’re tracking 309 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07546188Recruiting
AI System to Help Lymphoma Patients Take Oral Medications
This trial tests an artificial intelligence (AI) system designed to predict and help prevent medication non-compliance—meaning skipped or missed doses—in lymphoma patients taking oral (by-mouth) therapies. The goal is to catch problems early and support patients in taking their medications as prescribed.
Charleroi, HainautAges 18 years+ - NCT07566377RecruitingPhase 2
Cord Blood Transplant for Children and Young Adults With Blood Cancer
This study tests whether using cord blood stem cells (collected from umbilical cords after birth) can help treat high-risk blood cancers in children and young adults when a matched donor is not quickly available. Cord blood transplants may help prevent cancer from coming back.
New York, New YorkAges Up to 26 years - NCT07582432RecruitingPhase 3
Gamunex for Blood Cancer Patients With Low Antibodies
This trial tests whether Gamunex, an antibody replacement therapy, helps patients with chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma who have low immunoglobulin (antibody) levels. The treatment may reduce infections and improve how well the body fights disease.
St. Petersburg, FloridaAges 18 years+ - NCT07609030Recruiting
Brain Training During CAR-T Cell Cancer Treatment
This study tests whether special brain exercises can help protect thinking and memory skills during CAR-T cell therapy—a newer cancer treatment for certain blood cancers. Researchers want to see if training your brain during treatment reduces side effects on memory and mental function.
Columbus, OhioAges 18 years+ - NCT07623850RecruitingPhase 1
Early Study of JLM019 Injection for Advanced Cancers
This is an early-stage trial testing a new cancer treatment called JLM019 in patients with advanced solid tumors or lymphomas that haven't responded to other treatments. The study aims to find the right dose and see how well the drug works and how patients tolerate it.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07628738RecruitingPhase 2
Lower-dose radiation for early-stage NK/T-cell lymphoma after chemotherapy
This study tests whether patients with a specific type of blood cancer (NK/T-cell lymphoma) in the nose or sinuses who have responded well to chemotherapy can be safely treated with reduced radiation doses instead of standard high-dose radiation. The goal is to reduce side effects while maintaining effective treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07652580Recruiting
Toxins, immunity, and B-cell lymphoma
This study looks at how exposure to toxins might affect your immune system if you have B-cell non-Hodgkin lymphoma. You'll provide blood and skin samples, plus have your genes sequenced, to help researchers find links between environmental exposures and lymphoma.
Bethesda, MarylandAges 4 years+ - NCT06223542RecruitingPhase 1
TAK-243 for advanced cancers that haven't responded to other treatments
This trial tests a new drug called TAK-243 for people with advanced cancers (solid tumors or lymphomas) that have not responded to other treatments. It aims to see if the drug is safe and how well it works.
Bethesda, MarylandAges 18 years+ - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
Birmingham, AlabamaAges 18 years+ - NCT03938987RecruitingPhase 1/Phase 2
CAR T-cell therapy for CD19-positive aggressive lymphoma or ALL
This trial tests a lab-made immune therapy (CAR T-cells) that targets CD19, a marker found on certain lymphoma and leukemia cells. It’s for people whose lymphoma or ALL came back or did not respond to standard treatments, with the goal of getting the treatment to attack the cancer.
Calgary, AlbertaAges 2–70 - NCT04544592RecruitingPhase 1/Phase 2
CD19 CAR-T for children and young adults with B-cell blood cancers
This trial tests a one-time, lab-made immune cell treatment (CD19 CAR-T) for certain B-cell blood cancers in children and young adults. It may help people whose leukemia or lymphoma is not responding to standard treatment or has come back.
Aurora, ColoradoAges 1 month–30 years - NCT04771572RecruitingPhase 1
Oral drug LP-118 for relapsed blood cancers
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
Chicago, IllinoisAges 13 years+ - NCT05425992Recruiting
Spanish-speaking families with leukemia or lymphoma
This study aims to improve communication and strengthen a child’s “medical home” (the main care team and coordination) for Spanish-speaking families. It focuses on families receiving cancer care at the Center for Cancer and Blood Disorders (CCBD).
Aurora, ColoradoAges Up to 22 years - NCT05702853RecruitingPhase 1/Phase 2
CAR T-cell therapy after CD34 selection for CD19 lymphoma or CLL
This Phase 1/2 study tests a customized type of immune cell treatment (CD19 CAR T-cells) for people with certain relapsed or hard-to-treat lymphomas or CLL/SLL. It aims to improve control of disease by targeting the CD19 marker on cancer cells.
Charleston, South CarolinaAges 18 years+ - NCT06522932RecruitingPhase 1
PET imaging study for people getting CAR-T therapy for lymphoma
This trial tests a special PET imaging agent (64Cu-GRIP B) to see if it can help track how well CAR-T therapy is working in people with non-Hodgkin lymphoma. It is for patients who have had at least one prior treatment and are scheduled to receive a standard CD19-targeting CAR-T product.
San Francisco, CaliforniaAges 18 years+ - NCT04195633RecruitingPhase 2
Haploidentical donor stem cell transplant to treat blood cancers
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
Seattle, WashingtonAges 6 months+ - NCT06098430Recruiting
Quality of life in NLPHL patients
This study looks at how people with a rare type of Hodgkin lymphoma (NLPHL) feel about their health and quality of life. By filling out surveys, you can help doctors understand what really matters to patients like you.
Palo Alto, CaliforniaAges 8 years+ - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Los Angeles, CaliforniaAges 1–21 - NCT04288726RecruitingPhase 1
CAR T-cell trial for CD30-positive lymphomas that came back
This early-phase study tests a donor-made immune cell treatment designed to attack CD30-positive lymphomas that are relapsed or refractory. If you qualify, it could help by finding a safer, effective way to control the lymphoma using engineered T-cells.
Houston, TexasAges 12–75 - NCT07284433RecruitingPhase 1/Phase 2
Donor cell therapy for B-cell blood cancers
This trial tests a new treatment made from donor cells that target two proteins (CD19 and CD20) found on certain blood cancer cells. It may be an option for people whose B-cell lymphoma or chronic lymphocytic leukemia has come back or hasn't responded to at least two prior treatments.
Chicago, IllinoisAges 18 years+ - NCT05544968RecruitingPhase 1
CD30-targeted cell treatment for hard-to-treat blood cancers
This Phase 1 trial studies an experimental treatment that targets a marker called CD30 on cancer cells. It is for adults with certain relapsed or refractory CD30-positive blood cancers to see how well the treatment works and what side effects it causes.
Milwaukee, WisconsinAges 18 years+
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for non-hodgkin lymphoma?
- Yes. Clin2 currently lists 309 recruiting non-hodgkin lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a non-hodgkin lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a non-hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.